We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+14.28%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.14B
AUM Growth
+$168M
Cap. Flow
-$21.7M
Cap. Flow %
-0.69%
Top 10 Hldgs %
62.21%
Holding
45
New
4
Increased
10
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$62M
2
NKTR icon
Nektar Therapeutics
NKTR
+$56.9M
3
IRON icon
Disc Medicine
IRON
+$43.2M
4
STRO icon
Sutro Biopharma
STRO
+$22.6M
5
AVR
Anteris Technologies
AVR
+$17.2M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$68.5M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$62.1M
3
RVMD icon
Revolution Medicines
RVMD
+$50.5M
4
RPTX
Repare Therapeutics
RPTX
+$26.9M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%

No holdings matched the selected filter criteria.

1 2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2026 Portfolio in Review

As of Q1 2026, BVF Inc held 45 positions worth $3.14B, up 5.7% from $2.97B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc's Q1 2026 filing shows 4 new, 10 increased, 11 reduced and 4 closed positions. Its largest new stake was Alkermes: 2,000,000 shares worth $70.7M. The largest sale was Abivax, an estimated $68.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • BVF Inc's largest Q1 2026 buy was Alkermes: 2,000,000 shares worth $70.7M.
  • BVF Inc added most to Nektar Therapeutics in Q1 2026, an estimated $56.9M increase.
  • BVF Inc's biggest Q1 2026 reduction was MoonLake Immunotherapeutics, cutting an estimated $62.1M.
  • BVF Inc fully exited Abivax in Q1 2026, selling an estimated $68.5M.
  • BVF Inc's ten largest holdings make up 62% of its $3.14B portfolio in Q1 2026.
  • BVF Inc opened 4 new positions and closed 4 in Q1 2026.
  • BVF Inc's portfolio value rose 5.7% quarter-over-quarter to $3.14B.

Based on BVF Inc's 13F filing for Q1 2026, filed 15 May 2026.